| Lv, Bin |
NCT06696261: A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome |
|
|
| Not yet recruiting | 3 | 342 | RoW | Lianxiaxiaopi Granules, a simulated agent of Lianxiaxiaopi Granules | Tasly Pharmaceutical Group Co., Ltd | Postprandial Distress Syndrome | 06/26 | 08/26 | | |
NCT05410652: Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method) |
|
|
| Completed | N/A | 1176 | RoW | Detection of fecal samples with diagnostic kit, Sanger Sequencing group, Bacterial culture and drug sensitivity test of gastric mucosa samples | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection, Helicobacter Pylori gyrA Levofloxacin Resistance Mutation, Fecal Drug Resistance Gene Detection, Helicobacter Pylori Infection, Susceptibility to | 09/23 | 10/23 | | |
| Huang, Xuan |
NCT04957407: The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning |
|
|
| Recruiting | N/A | 5000 | RoW | pepsinogen | Second Affiliated Hospital, School of Medicine, Zhejiang University | Gastric Cancer, Precancerous Lesion, Mechine Learning | 05/22 | 12/22 | | |
| Fan, Yihong |
NCT06609447: The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis |
|
|
| Recruiting | 4 | 100 | RoW | VSL#3, Placebo, Placebo (for VSL#3), Vedolizumab, Vedolizumab 300 mg Injection | Second Affiliated Hospital, School of Medicine, Zhejiang University | Ulcerative Colitis | 12/27 | 12/27 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Completed | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
NCT05387031: Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease |
|
|
| Recruiting | N/A | 239 | RoW | Ustekinumab, Stelara | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sixth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Soochow University, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Seventh Medical Center of PLA Army General Hospital, First People's Hospital of Hangzhou, Yangzhou University, Xian-Janssen Pharmaceutical Ltd. | Crohn Disease, Stricture; Bowel, Intestinal Stricture | 08/26 | 08/27 | | |
| Gu, Xidong |
NCT06016790: Exploring a Breast Cancer Early Screening Model Based on cfDNA |
|
|
| Completed | N/A | 792 | RoW | cfDNA sequencing | Second Affiliated Hospital, School of Medicine, Zhejiang University, OmixScience Institute | Breast Cancer, Breast Fibroadenoma, Breast Hypoplasia | 12/23 | 10/24 | | |
